Instead of a broad launch targeting primary care, Madrigal focused its specialty sales force on the 315,000 patients already diagnosed with moderate-to-severe MASH. This disciplined approach of targeting a specific, existing patient population allowed for efficient market penetration and rapid success.

While DUPIXENT successfully manages chronic inflammatory conditions, it takes weeks to work and doesn't stop all flare-ups. This creates a market opportunity for fast-acting therapeutics that address urgent, emergency room-level episodes, a scenario DUPIXENT is not designed for.

InflaRx's strategy targets the C5a pathway, implicated in many inflammatory conditions. By focusing on this single mechanism, their drug could potentially treat a wide range of diseases, from skin conditions to kidney disease, effectively creating a valuable "pipeline in a drug."

Crohn's disease is a higher bar for drug approval than ulcerative colitis, often due to fibrotic strictures. Abivax has presented preclinical data suggesting its drug has anti-fibrotic properties. This is a key differentiator, as therapies that fail in Crohn's often lack this effect, providing a mechanistic rationale for potential success.

In the crowded Inflammatory Bowel Disease (IBD) market, most drugs focus on immune suppression. MRM Health’s lead asset differentiates itself with a novel mechanism of action. It aims to restore the microbiome and heal the gut's epithelial lining, addressing the root cause of inflammation rather than just managing symptoms.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

The company's strategy for its IL-23 inhibitor isn't just a single drug approval. They follow an established industry model where one successful drug becomes a pipeline for multiple related inflammatory indications like psoriasis, Crohn's, and ulcerative colitis, dramatically expanding its market potential over time.

Despite many approved drugs for Inflammatory Bowel Disease (IBD), single-mechanism therapies consistently fail to get more than 30% of patients into remission. This recognized "therapeutic ceiling" exists because IBD is a multi-faceted disease. The next breakthrough requires attacking multiple biological pathways simultaneously with combination drugs to achieve significantly higher efficacy.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.